Injection of a hydrogel spacer to provide prostate-rectum separation during radiation therapy for prostate cancer is associated with decreased radiation-induced rectal toxic effects, according to a ...

BOSTON — An injected hydrogel that temporarily creates space between the otherwise contiguous rectum and prostate gland continues to benefit patients 3 years after radiation treatment for prostate ...

Originally described in 1917, low dose-rate (LDR) prostate brachytherapy represents the earliest form of radiotherapy for prostate cancer. 1 During the early years, seed placement through an open ...

Decision based on data involving use of SpaceOAR® hydrogel to protect surrounding tissue during radiotherapy to treat prostate cancer. BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Inc., a medical ...

Results published in the International Journal of Radiation Oncology Biology and Physics show on average no long-term declines in bowel and urinary quality of life for patients and 78% reduction in ...

WALTHAM, Mass.--(BUSINESS WIRE)--Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following cancer radiotherapy, today announced the ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest announcement is out from ...

Do elderly men (>75) harbor more aggressive prostate cancer? Comparison of decipher and PAM50 TESTS among different age groups. This is an ASCO Meeting Abstract from the 2019 Genitourinary Cancers ...

SpaceOAR System is an absorbable hydrogel spacer that is injected into the perirectal space between the prostate and rectum before radiotherapy for prostate cancer. After developing the final scope we ...

Decision based on data involving use of SpaceOAR® hydrogel to protect surrounding tissue during radiotherapy to treat prostate cancer. Augmenix, Inc., a medical technology company that develops, ...